William A. Hall, Dana C. Nickleach, Viraj A. Master, Roshan S. Prabhu, Peter J. Rossi, Karen Godette, Sherri Cooper and Ashesh B. Jani The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate Cancer 119
In patients who receive treatment for prostate cancer with radiation therapy, the C-reactive protein (CRP) levels are associated with biochemical failure-free survival on multivariable analysis. In the postradical prostatectomy setting, CRP is associated with prostate-specific antigen (PSA) levels in patients who have Gleason scores ≥8, those with pretreatment PSA levels >20 ng/mL, and high-risk patients. In the setting of treatment with definitive radiation therapy, CRP is associated with PSA for intermediate-risk and high-risk patients and for those with pretreatment PSA levels >20 ng/mL.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf